Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 1939-1945

  Meagher, A K ^a   Passarell, J A ^a   Cirincione, B B ^a   Van Wart, S A ^a   Liolios, K ^a   Babinchak, T ^b   Ellis Grosse, E J ^b   Ambrose, P G ^c,d  

^a Albany Medical College   (United States)

^b PFIZER INC   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; TIGECYCLINE; VANCOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEADY STATE; STREPTOCOCCUS; STREPTOCOCCUS INFECTION; TREATMENT RESPONSE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; TREATMENT OUTCOME;

EID: 34250164635     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01084-06     Document Type: Article

References (24)

1. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
2. Babinchak, T., E. Ellis-Grosse, N. Dartois, G. M. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl.):S354-S367.
3. Christianson, J., D. Andes, and W. Craig. 2001. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1103.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
5. Doern, G. V., R. N. Jones, M. A. Pfaller, K. C. Kugler, and M. L. Beach. 1999. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn. Microbiol. Infect. Dis. 34:65-72.
6. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
7. Ellis-Grosse, E. J., T. Babinchak, N. Dartois, G. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5):S341-S353.
8. Exposure-Response Working Group. 2003. FDA guidance for industry exposure-response relationships: study design, data analysis, and regulatory applications. [Online.] http://www.fda.gov/cber/gdlns/exposure.htm. U.S. Department of Health and Human Services, Rockville, MD.
9. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
10. Gerding, D. N. 1995. Foot infections in diabetic patients: the role of anaerobes. Clin. Infect. Dis. 20(Suppl. 2):S283-S288.
11. Jelliffe, R. W. 1973. Creatinine clearance: bedside estimate. Ann. Intern. Med. 79:604-605. (Letter.)
12. MacGowan, A., C. Rogers, and K. Bowker. 2001. In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models? Clin. Infect. Dis. 33(Suppl. 3):S214-S220.
13. Mathsoft, Inc. 2000. S-Plus 6.0 for UNIX guide to statistics, vol. 1 and 2. MathSoft, Inc., Seattle, WA.
14. Muralidharan, G., M. Micalizzi, J. Speth, D. Raible, and S. Troy. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.
15. Nichols, R. L. 1999. Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 44(Suppl. A):19-23.
16. Oliva, M. E., A. Rekha, A. Yellin, J. Pasternak, M. Campos, G. M. Rose, T. Babinchak, E. J. Ellis-Grosse, and E. Loh. 2005. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect. Dis. 5:88-100.
17. Orangio, G. R., S. D. Pitlick, P. Della Latta, L. J. Mandel, C. Marino, J. J. Guarneri, J. A. Giron, and I. B. Margolis. 1984. Soft tissue infections in parenteral drug abusers. Ann. Surg. 199:97-100.
18. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
19. SAS Institute, Inc. 1999. SAS/STAT user's guide, version 8.2. SAS Institute, Inc., Cary, NC.
20. Summanen, P. H., D. A. Talan, C. Strong, M. McTeague, R. Bennion, J. E. Thompson, Jr., M. L. Vaisanen, G. Moran, M. Winer, and S. M. Finegold. 1995. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin. Infect. Dis. 20(Suppl. 2):S279-S282.
21. Talan, D. A., D. M. Citron, F. M. Abrahamian, G. J. Moran, and E. J. Goldstein. 1999. Bacteriologic analysis of infected dog and cat bites. N. Engl. J. Med. 340:85-92.
22. van Ogtrop, M. L., D. Andes, T. J. Stamstad, B. Conklin, W. J. Weiss, W. A. Craig, and O. Vesga. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44:943-949.
23. Van Wart, S. A., J. S. Owen, E. A. Ludwig, A. K. Meagher, J. M. Korth-Bradley, and B. B. Cirincione. 2006. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin-structure infections. Antimicrob. Agents Chemother. 50:3701-3703.
24. Wilcox, M. H. 2005. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections. J. Chemother. 17(Suppl. 1):23-29.